NCT04469556 2026-02-20
PASS-01
University Health Network, Toronto
Phase 2 Completed
Clinical Trials
13 trialsNCT06752811 2026-02-10
pompom
Shanghai Yizhong Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT07342725 2026-01-15
Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Ruijin Hospital
Phase 1/2 Not yet recruiting
NCT06076837 2026-01-12
The Seven Trial: Exploiting the Unfolded Protein Response
HonorHealth Research Institute
Phase 1 Active not recruiting
NCT07230301 2025-11-17
Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions
Jinling Hospital, China
Phase 2 Not yet recruiting
NCT07231094 2025-11-17
A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer
The Third Xiangya Hospital of Central South University
Phase EARLY_PHASE1 Not yet recruiting
NCT07086352 2025-07-25
Influence of Metastatic Sites on Survival Outcomes and Predictive Factors for Extended Survival in Metastatic Pancreatic Cancer a Retrospective Study
Assiut University
Not yet recruiting
NCT07040228 2025-06-27
A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Phase 1/2 Recruiting
NCT06921252 2025-04-10
Does Recurrent Pancreatic Cancer Really Have Similar Outcome Compared With Primary Metastatic Pancreatic Cancer?
Kochi University
Completed
NCT06888648 2025-03-21
Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
Zhejiang University
Phase 1/2 Not yet recruiting
NCT06690528 2024-11-15
SONAR
Azienda Ospedaliera di Padova
Phase 2 Recruiting
NCT06155136 2024-04-22
NALLONG
Servier
Active not recruiting
NCT03504423 2023-01-03
Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
Cornerstone Pharmaceuticals
Phase 3 Completed